Drug Target Review – Issue 3 2020
Posted: 8 September 2020 | Drug Target Review | No comments yet
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets to control M. tuberculosis.
This issue includes:
- ANTIBODIES
Oncology meets immunology – antibody-mediated regulation of the immune response
Aparajita Dubey, CRAMbridge - TARGETS
Exploring the intra-protein non-covalent interactions in the S1 domain of the SARS-CoV-2 S1 Spike protein
Oscar Bastidas, University of Minnesota
- FLOW CYTOMETRY
Flow cytometry in neglected tropical diseases – a focus on leishmaniasis
Professor Paul Kaye, University of York
- ASSAYS
Exploring new drug targets in Alzheimer’s disease
Monika Schmidt, University of Hradec Kralove
Sheraz Gul, Fraunhofer Institute
- NGS
NGS: offering a glimmer of hope in the fight against COVID-19
Pushpanathan Muthuirulan, Harvard University
- CNS/NEUROSCIENCE
Cocaine and the brain: identifying targets for addiction therapies
Hannah Balfour, Drug Target Review
- SYNTHETIC BIOLOGY
Understanding the limits of synthetic biology through the origins of SARS-CoV-2
Marc Baiget Francesch, International Journal of Molecular Sciences
The rest of this content is restricted - login or subscribe free to access
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here